Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines

Experimental Neurology

Volumn 233, Issue 2, 2012, Pages 799-806

  Zhang, Weiguang ^a,b   Khatibi, Nikan H ^c   Yamaguchi Okada, Mitsuo ^d   Yan, Junhao ^b,c   Chen, Chunhua ^b   Hu, Qin ^b   Meng, Haiwei ^a   Han, Hongbin ^e   Liu, Shuwei ^a   Zhou, Changman ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^d Seirei Yokohama Hospital   (Japan)

^e PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Anti proliferation; MTOR pathway; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

AZD 8055; CYCLINE; DIMETHYL SULFOXIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S 1555; S6 KINASE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; DOGS; FEMALE; MALE; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; SIROLIMUS; SUBARACHNOID HEMORRHAGE; TOR SERINE-THREONINE KINASES; VASOSPASM, INTRACRANIAL;

EID: 84856555903     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.046     Document Type: Article

References (22)

1. Bhardwaj A. SAH-induced cerebral vasospasm: unraveling molecular mechanisms of a complex disease. Stroke 2003, 34:427-433.
2. Borel C.O., McKee A., Parra A., Haglund M.M., Solan A., Prabhakar V., Sheng H., Warner D.S., Niklason L. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke 2003, 34:427-433.
3. Carew J.S., Kelly K.R., Nawrocki S.T. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target. Oncol. 2011, 6:17-27.
4. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C., Guichard S., Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
5. Ciuffreda L., Di S.C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 2010, 10:484-495.
6. Corradetti M.N., Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 2006, 25:6347-6360.
7. Debdi M., Seylaz J., Sercombe R. Early changes in rabbit cerebral artery reactivity after subarachnoid hemorrhage. Stroke 1992, 23:1154-1162.
8. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
9. Gera J., Lichtenstein A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk. Lymphoma 2011, 52:1857-1866.
10. Kusaka G., Kimura H., Kusaka I., Perkins E., Nanda A., Zhang J.H. Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage. J. Neurosurg. 2003, 99:383-390.
11. Liao Q., Shi D.H., Zheng W., Xu X.J., Yu Y.H. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats. Eur. J. Pharmacol. 2010, 641:179-186.
12. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 1995, 76:412-417.
13. McGirt M.J., Lynch J.R., Blessing R., Warner D.S., Friedman A.H., Laskowitz D.T. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002, 51:1128-1134.
14. Pignataro G., Capone D., Polichetti G., Vinciguerra A., Gentile A., Di R.G., Annunziato L. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Curr. Opin. Pharmacol. 2011, 11:378-394.
15. Shirao S., Yoneda H., Ishihara H., Kajiwara K., Suzuki M. A proposed definition of symptomatic vasospasm based on treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan: Consensus 2009, a project of the 25 Spasm Symposium. Surg. Neurol. Int. 2011, 2:74.
16. Varsos V.G., Liszczak T.M., Han D.H., Kistler J.P., Vielma J., Black P.M., Heros R.C., Zervas N.T. Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a "two-hemorrhage" canine model. J. Neurosurg. 1983, 58:11-17.
17. Yamaguchi M., Zhou C., Nanda A., Zhang J.H. Ras protein contributes to cerebral vasospasm in a canine double-hemorrhage model. Stroke 2004, 35:1750-1755.
18. Yan J., Chen C., Lei J., Yang L., Wang K., Liu J., Zhou C. 2-Methoxyestradiol reduces cerebral vasospasm after 48hours of experimental subarachnoid hemorrhage in rats. Exp. Neurol. 2006, 202:348-356.
19. Zhang J.H. Role of MAPK in cerebral vasospasm. Drug News Perspect. 2001, 14:261-267.
20. Zhou C., Yamaguchi M., Kusaka G., Schonholz C., Nanda A., Zhang J.H. Caspase inhibitors prevent endothelial apoptosis and cerebral vasospasm in dog model of experimental subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2004, 24:419-431.
21. Zhou C., Yamaguchi M., Colohan A.R., Zhang J.H. Role of p53 and apoptosis in cerebral vasospasm after experimental subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2005, 25:572-582.
22. Zoghbi H.Y., Okumura S., Laurent J.P., Fishman M.A. Acute effect of glycerol on net cerebrospinal fluid production in dogs. J. Neurosurg. 1985, 63:759-762.